Several explorative studies have shown the high molecular heterogeneity of gliomas such as the isocitrate dehydrogenase 1 (IDH1) gene, and O-6-methylguanine-DNA-methyltransferase (MGMT) promoter statuses also provide important prognostic information in GBM to advance personalized treatment and translational medicine. This evidence concerns the gene MGMT and glioblastoma.